Halozyme Therapeutics Stock Market Value
| HALO Stock | USD 48.20 0.27 0.56% |
| Symbol | Halozyme |
Halozyme Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.721 | Earnings Share 3.02 | Revenue Per Share 7.431 | Quarterly Revenue Growth 0.343 | Return On Assets 0.1487 |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Halozyme Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Halozyme Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Halozyme Therapeutics.
| 06/08/2023 |
| 11/29/2024 |
If you would invest 0.00 in Halozyme Therapeutics on June 8, 2023 and sell it all today you would earn a total of 0.00 from holding Halozyme Therapeutics or generate 0.0% return on investment in Halozyme Therapeutics over 540 days. Halozyme Therapeutics is related to or competes with Agios Pharm, Insmed, Ultragenyx, Biomarin Pharmaceutical, Alnylam Pharmaceuticals, Exelixis, and Alector. Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Irela... More
Halozyme Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Halozyme Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Halozyme Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.12) | |||
| Maximum Drawdown | 28.41 | |||
| Value At Risk | (6.75) | |||
| Potential Upside | 3.9 |
Halozyme Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Halozyme Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Halozyme Therapeutics' standard deviation. In reality, there are many statistical measures that can use Halozyme Therapeutics historical prices to predict the future Halozyme Therapeutics' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.51) | |||
| Total Risk Alpha | (0.91) | |||
| Treynor Ratio | (0.23) |
Halozyme Therapeutics Backtested Returns
Halozyme Therapeutics holds Efficiency (Sharpe) Ratio of -0.0781, which attests that the entity had a -0.0781% return per unit of risk over the last 3 months. Halozyme Therapeutics exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Halozyme Therapeutics' Standard Deviation of 3.76, risk adjusted performance of (0.06), and Market Risk Adjusted Performance of (0.22) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 1.51, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Halozyme Therapeutics will likely underperform. At this point, Halozyme Therapeutics has a negative expected return of -0.3%. Please make sure to check out Halozyme Therapeutics' information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Halozyme Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.3 |
Weak reverse predictability
Halozyme Therapeutics has weak reverse predictability. Overlapping area represents the amount of predictability between Halozyme Therapeutics time series from 8th of June 2023 to 4th of March 2024 and 4th of March 2024 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Halozyme Therapeutics price movement. The serial correlation of -0.3 indicates that nearly 30.0% of current Halozyme Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.3 | |
| Spearman Rank Test | -0.3 | |
| Residual Average | 0.0 | |
| Price Variance | 59.87 |
Halozyme Therapeutics lagged returns against current returns
Autocorrelation, which is Halozyme Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Halozyme Therapeutics' stock expected returns. We can calculate the autocorrelation of Halozyme Therapeutics returns to help us make a trade decision. For example, suppose you find that Halozyme Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Halozyme Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Halozyme Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Halozyme Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Halozyme Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Halozyme Therapeutics Lagged Returns
When evaluating Halozyme Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Halozyme Therapeutics stock have on its future price. Halozyme Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Halozyme Therapeutics autocorrelation shows the relationship between Halozyme Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Halozyme Therapeutics.
Regressed Prices |
| Timeline |
Pair Trading with Halozyme Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Halozyme Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Halozyme Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Halozyme Stock
Moving against Halozyme Stock
| 0.6 | EWTX | Edgewise Therapeutics | PairCorr |
| 0.59 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.58 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.47 | GANX | Gain Therapeutics | PairCorr |
| 0.44 | GILD | Gilead Sciences | PairCorr |
The ability to find closely correlated positions to Halozyme Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Halozyme Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Halozyme Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Halozyme Therapeutics to buy it.
The correlation of Halozyme Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Halozyme Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Halozyme Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Halozyme Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Halozyme Therapeutics Correlation, Halozyme Therapeutics Volatility and Halozyme Therapeutics Alpha and Beta module to complement your research on Halozyme Therapeutics. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.
Halozyme Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.